Kadcyla is an antibody-drug conjugate engineered to deliver potent chemotherapy directly to HER2-positive cancer cells, potentially limiting damage to healthy tissues. It combines two anti-cancer properties joined together by a stable linker: the HER2-targeting properties of trastuzumab (the active ingredient in Herceptin) and the chemotherapy agent DM1.

KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for:

• The treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:

  1. Received prior therapy for metastatic disease, or

  2. Developed disease recurrence during or within six months of completing adjuvant therapy.

• The adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.

If a patient becomes pregnant while receiving KADCYLA, or within 7 months following the last dose of Kadcyla, please immediately report pregnancy to the local Roche Adverse Event Line at +92 301 8287010 or email at pakistan.drug_safety@roche.com

M-PK-00001196